While Xeris Biopharma Holdings Inc has underperformed by -1.13%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, XERS rose by 133.04%, with highs and lows ranging from $8.02 to $2.48, whereas the simple moving average jumped by 75.77% in the last 200 days.
On August 12, 2025, H.C. Wainwright started tracking Xeris Biopharma Holdings Inc (NASDAQ: XERS) recommending Buy. A report published by Piper Sandler on November 11, 2024, Downgraded its rating to ‘Neutral’ for XERS. Oppenheimer also rated XERS shares as ‘Outperform’, setting a target price of $5 on the company’s shares in an initiating report dated March 28, 2024. Craig Hallum Initiated an Buy rating on August 28, 2023, and assigned a price target of $4.50. Jefferies initiated its ‘Buy’ rating for XERS, as published in its report on October 21, 2022. Craig Hallum’s report from April 28, 2022 suggests a price prediction of $6.50 for XERS shares, giving the stock a ‘Buy’ rating. SVB Leerink also rated the stock as ‘Outperform’.
Analysis of Xeris Biopharma Holdings Inc (XERS)
Further, the quarter-over-quarter increase in sales is 48.84%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Xeris Biopharma Holdings Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. Taking into account the quick ratio of the company, currently set at 1.24, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 2.51M can be a very valuable indicator of volatility for XERS stock. On a monthly basis, the volatility of the stock is set at 5.61%, whereas on a weekly basis, it is put at 2.73%, with a gain of 4.08% over the past seven days. Furthermore, long-term investors anticipate a median target price of $9.00, showing growth from the present price of $7.9, which can serve as yet another indication of whether XERS is worth investing in or should be passed over.
How Do You Analyze Xeris Biopharma Holdings Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 7.21%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 56.37% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
